Loading...
XASX
CYC
Market cap44mUSD
Jul 10, Last price  
0.53AUD
1D
2.94%
1Q
-34.38%
Jan 2017
-41.79%
IPO
-75.69%
Name

Cyclopharm Ltd

Chart & Performance

D1W1MN
XASX:CYC chart
P/E
P/S
2.04
EPS
Div Yield, %
Shrs. gr., 5y
7.53%
Rev. gr., 5y
17.11%
Revenues
32m
+17.24%
10,331,83211,128,22410,888,26913,112,4209,464,60510,314,50610,743,82411,882,13412,046,79712,582,51914,385,50713,188,75213,404,22214,078,80114,676,15717,704,57423,218,79726,339,38927,572,58132,325,256
Net income
-17m
L+30.48%
2,027,9801,131,2391,757,0622,044,490450,106-956,220-1,044,127-779,9544,065,5634,793,047891,368-1,524,571-35,456-2,912,440-6,043,636-5,040,166-6,611,515-4,700,806-13,197,618-17,219,906
CFO
-17m
L+37.82%
146,0991,486,0293,691,033-90,960563,627369,285706,7064,468,7804,154,834654,794-682,121-1,107,335-489,340-8,934,868-1,629,410-6,664,485-7,197,632-12,574,405-17,329,447
Dividend
Sep 01, 20230.00764855 AUD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Cyclopharm Limited is an international enterprise specializing in the production and global distribution of medical devices and radiopharmaceuticals, with operations spanning Asia Pacific, Europe, Canada, and other regions. The company's business activities are structured into two principal divisions: Technegas and Molecular Imaging. Through its Technegas segment, Cyclopharm supplies diagnostic apparatus and accompanying consumables critical for clinicians in the identification of pulmonary embolisms, alongside distributing third-party offerings to the broader diagnostic imaging sector. Conversely, the Molecular Imaging division provides advanced radiopharmaceutical agents essential for medical practitioners diagnosing conditions such as cancer, various neurological disorders, and cardiac diseases. Cyclopharm primarily serves nuclear medicine departments. Established in 1986, the company's corporate headquarters are located in Kingsgrove, Australia.
IPO date
Jan 18, 2007
Employees
63
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT